Arcus Biosciences, Inc.

NYSE:RCUS

Biotechnology

Healthcare
$15.76 -0.39%

-$0.09 today

Market cap
$2.27B
Beta
0.84
P/E (TTM)
-8.2
EPS (TTM)
-$2.94
52W Low $7.91High $28.72

Volume 1.97M

Average 1.17M

RCUS EBITDA Margin

EBITDA as a percentage of revenue.

Arcus Biosciences, Inc.NYSE: RCUS

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin narrows to -207.3%

EBITDA Margin was -207.3% in Q2 FY2026, down 209.8 pp from a year earlier. On a trailing-twelve-month basis it was -358.1%, down 250.5 pp year over year. Over 3 fiscal years it widened by 94.7 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 10 analysts of -507.9% for the fiscal year ending Dec 2026, down from -135.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-207.3%+516.2 pp QoQ
Last fiscal yearDec 2025
-135.6%-31.4 pp YoY
LTMJun 2026
-358.1%-250.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-209.8 pp-931.1 pp-721.3 pp
1 year-31.4 pp-372.2 pp-340.9 pp
3 years+94.7 pp-605.2 pp-700.0 pp
5 years+157.3 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-135.6%
Year-over-year change
-31.4pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How RCUS compares with its peers on the latest reported figures

  • RCUS's LTM Jun 2026 EBITDA Margin of -358.1% is the 3rd highest of the 8 companies compared; the peer median is -527.0%.
  • Its year-over-year change of -250.5 pp is the 5th highest of 7, against a peer median of +176.5 pp.
  • Over three fiscal years its change of +94.7 pp compares with a peer median of +623.5 pp.
RCUS Competitors Peer median
EBITDA Margin for RCUS and competitors
Company Period LTM level YoY 3-year change
LQDALiquidia CorporationLTM Jun 202639.4% +670.4 pp+192.5 pp
BEAMBeam Therapeutics Inc.LTM Jun 2026-40.5% +584.3 pp+435.7 pp
RCUSArcus Biosciences, Inc.LTM Jun 2026-358.1% -250.5 pp+94.7 pp
VRDNViridian Therapeutics, Inc.LTM Jun 2026-516.8% +111160.6 pp+6811.5 pp
OCULOcular Therapeutix, Inc.LTM Mar 2026-527.0% -231.3 pp-361.8 pp
IBRXImmunityBio, Inc.LTM Sep 2026-550.8% -269.0 pp+146419.7 pp
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026-633.4% -2566.2 pp+811.4 pp
DNLIDenali Therapeutics Inc.LTM Jun 2026-13823.7% ——
COGTCogent Biosciences, Inc.FY2025— ——
Peer median (excluding RCUS) -527.0%+176.5 pp+623.5 pp

Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue383M112M117M258M247M
Cost of Revenue000010M
Gross Profit383M112M117M258M237M
Gross Margin100.0%100.0%100.0%100.0%96.0%
Research & Development257M288M340M448M523M
Selling, General & Admin72M104M117M120M110M
Operating Expenses329M392M457M588M623M
Depreciation & Amortization4M6M8M10M10M
EBITDA59M(258M)(291M)(269M)(335M)
EBITDA Margin15.4%-230.4%-248.7%-104.3%-135.6%
Operating Income54M(280M)(340M)(330M)(386M)
Operating Margin14.1%-250.0%-290.6%-127.9%-156.3%
Interest Income1M16M41M52M41M
Interest Expense02M2M4M8M
Other Income / Expenses1M14M39M47M33M
Income Before Tax55M(266M)(301M)(283M)(353M)
Pre-Tax Margin14.4%-237.5%-257.3%-109.7%-142.9%
Income Tax Expense2M1M6M1M0
Net Income53M(267M)(307M)(283M)(353M)
Net Margin13.8%-238.4%-262.4%-109.7%-142.9%
EPS (Basic)0.76(3.71)(4.15)(3.14)(3.29)
EPS (Diluted)0.71(3.71)(4.15)(3.14)(3.29)
Weighted Avg Shares69.35M72M74M90.1M107.4M
Weighted Avg Shares (Diluted)73.97M72M74M90.1M107.4M

Arcus Biosciences, Inc.

NYSE:RCUS

Intrinsic Alpha fair value

Locked

Current Price

$15.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.